International Journal of Drug Policy
Volume 21, Issue 6 , Pages 501-506, November 2010

High and low threshold service provision in drug-free settings: Practitioner views

Radford University, Waldron 210, P.O. Box 6958, Radford, VA 24142, United States

Received 23 November 2009; received in revised form 5 March 2010; accepted 16 March 2010. published online 15 April 2010.

Abstract 

Background

In the United States, drug-free (non-drug substitution) treatment programmes are informed by an abstinence-only, disease model. Some critics believe this model hinders treatment service utilization and retention. An alternative public health model of harm reduction suggests that drug services should have a “low-threshold” for entry and retention such that they are offered with few or no conditions, such as abstinence from drug use.

Methods

Using semi-structured qualitative interviews with 15 practitioners from 9 outpatient drug-free agencies, this study examined beliefs about low threshold service provisions.

Results

Respondents identified certain conditions for drug services as clinically and programmatically appropriate and necessary to ensure safety. Factors relevant to outpatient services, drug use and client dynamics were also cited. Respondents tended to support service conditions to inform treatment planning and practices.

Conclusions

Practitioners in these settings accept and support some threshold of imposed service conditions as useful in treatment and service planning. When outpatient services are terminated clinically appropriate services are offered instead. Concerns for service accessibility should focus on the availability of medically intensive services.

Keywords: Disease model, Harm reduction, Low threshold, Outpatient, Drug use

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(10)00059-9

doi:10.1016/j.drugpo.2010.03.005

International Journal of Drug Policy
Volume 21, Issue 6 , Pages 501-506, November 2010